Abstract

Although vaccination against various pathogens is integral to health management of swine, vaccines against parasites have not yet been commercialized for the use in pigs. The incentive to develop and commercialize anti-parasitic vaccines in swine are twofold; on the one hand parasitic diseases which are economically important, such as ascarosis and neonatal coccidiosis, could be controlled in a sustainable manner; on the other hand, the transmission of zoonotic parasites, such as Toxoplasma gondii or Cysticercus cellulosae, could be effectively interrupted. Although experimental research indicates that vaccination against a number of porcine parasites is feasible, development and commercialization of potential vaccines so far has been very slow, as our knowledge on the host-parasite interplay in porcine parasitic infections is still very limited. In the light of growing concerns regarding consumer health and antiparasitic drug resistance, however, it is timely to re-direct R&D efforts to the development of biological control options.

Highlights

  • Vaccination against various pathogens is integral to health management of swine, vaccines against parasites have not yet been commercialized for the use in pigs

  • Compared to viral and bacterial pathogens, there is a general scarcity for antiparasite vaccines; only two anti-nematode vaccines, one anti-tick-vaccine and a handful of antiprotozoal vaccines are available for domestic animals

  • For many parasitic infections the development of immunity is slow, and especially in livestock animals, the required time is too short for the vaccine to be of value before animals go to slaughter

Read more

Summary

Introduction

Vaccination against various pathogens is integral to health management of swine, vaccines against parasites have not yet been commercialized for the use in pigs. For host species with a fast turnover the development of anti-parasite vaccines are considered too expensive and especially in intensive pig (or poultry) production chemical control is cheaper, easier to apply and is considered to have a broader market.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call